J. Silverberg, “Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis”, J of Skin, vol. 5, no. 1, p. s9, Jan. 2021.